Condition: Diabetes Mellitus, Type 2 · Heart Failure · Chronic Kidney Diseases · Sponsor: Herlev and Gentofte Hospital
The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com
This description comes directly from the study's public registry record.
Morten Schou, Professor · 004540523920 · morten.schou.04@regionh.dk
Daniel M. Christensen, MD, PhD · 004526248546 · dmc@dadlnet.dk
Always discuss trial participation with your own doctor first.
| Bispebjerg Hospital | Copenhagen, Denmark | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Herlev and Gentofte Hospital | Herlev, Denmark | Recruiting |
| Steno Diabetes Center Copenhagen | Herlev, Denmark | Recruiting |
| Nordsjællands Hospital | Hillerød, Denmark | Recruiting |
| Holbæk Sygehus | Holbæk, Denmark | Recruiting |
| Hvidovre Hospital | Hvidovre, Denmark | Recruiting |
| Sjællands Universitetshospital | Køge, Denmark | Recruiting |
| Nykøbing F. Sygehus | Nykøbing Falster, Denmark | Recruiting |
| Sjællands Universitetshospital | Roskilde, Denmark | Recruiting |
| Bornholms Hospital | Rønne, Denmark | Recruiting |
| Slagelse Sygehus | Slagelse, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06642272